Find slides from real investment banking decks

Browse 137,735 classified slides from investment banking pitch decks.

5,473–5,520 of 137,735 slidesPage 115 of 2870

Timeline slide 30 from Advent — Next-generation Ht-pem Fuel Cell Technology

Advent — Next-generation Ht-pem Fuel Cell Technology · Slide 30

2021

Financial Analysis slide 31 from Advent — Next-generation Ht-pem Fuel Cell Technology

Advent — Next-generation Ht-pem Fuel Cell Technology · Slide 31

2021

Text slide 32 from Advent — Next-generation Ht-pem Fuel Cell Technology

Advent — Next-generation Ht-pem Fuel Cell Technology · Slide 32

2021

Cover slide 33 from Advent — Next-generation Ht-pem Fuel Cell Technology

Advent — Next-generation Ht-pem Fuel Cell Technology · Slide 33

2021

Cover slide 1 from Advent — Title Slide

Advent — Title Slide · Slide 1

2021

Text slide 2 from Advent — Title Slide

Advent — Title Slide · Slide 2

2021

Case Study slide 3 from Advent — Title Slide

Advent — Title Slide · Slide 3

2021

Comparison slide 4 from Advent — Title Slide

Advent — Title Slide · Slide 4

2021

Comparison slide 5 from Advent — Title Slide

Advent — Title Slide · Slide 5

2021

Text slide 6 from Advent — Title Slide

Advent — Title Slide · Slide 6

2021

Process slide 7 from Advent — Title Slide

Advent — Title Slide · Slide 7

2021

Cover slide 8 from Advent — Title Slide

Advent — Title Slide · Slide 8

2021

Cover slide 1 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 1

Text slide 2 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 2

Text slide 3 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 3

Comparison slide 4 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 4

Timeline slide 5 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 5

Dashboard slide 6 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 6

Chart slide 7 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 7

Case Study slide 8 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 8

Chart slide 9 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 9

Chart slide 10 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 10

Table slide 11 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 11

Text slide 12 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 12

Text slide 13 from Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D)

Aeglea Biotherapeutics — 1 Year Data from First in Human Study of Pegzilarginase for the Treatment of Arginase 1 Deficiency (ARG1-D) · Slide 13

Cover slide 1 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 1

2023

Text slide 2 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 2

2023

Text slide 3 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 3

2023

Financial Analysis slide 4 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 4

2023

Table slide 5 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 5

2023

Chart slide 6 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 6

2023

Chart slide 7 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 7

2023

Chart slide 8 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 8

2023

Framework slide 9 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 9

2023

Comparison slide 10 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 10

2023

Comparison slide 11 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 11

2023

Comparison slide 12 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 12

2023

Table slide 13 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 13

2023

Table slide 14 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 14

2023

Chart slide 15 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 15

2023

Comparison slide 16 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 16

2023

Comparison slide 17 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 17

2023

Framework slide 18 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 18

2023

Comparison slide 19 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 19

2023

Chart slide 20 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 20

2023

Chart slide 21 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 21

2023

Comparison slide 22 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 22

2023

Comparison slide 23 from Aeglea Biotherapeutics — Corporate Overview

Aeglea Biotherapeutics — Corporate Overview · Slide 23

2023